ABSTRACT
About Erythropoietin Drugs

The global erythropoietin drugs market is expected to witness a slow growth rate during the forecast period. In 2016, EMEA dominated the market, followed by the Americas and APAC. India and China are the leading countries in the market in APAC. While Sandoz and Dr. Reddy's Laboratories dominate the erythropoietin (EPO) drugs market in India, the market in China is led by 3SBio and Beijing SL Pharmaceutical. EMEA is also witnessing positive growth, mainly due to an increase in the manufacture of EPO biosimilars by European vendors and the use of biosimilar products in this region. However, the situation in the US is complicated due to the formation of a new legislative body to govern biosimilar products.

Technavio’s analysts forecast the global erythropoietin drugs market to grow at a CAGR of 0.79% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global erythropoietin drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded and biosimilars used for the treatment of anemia due to renal diseases, cancer chemotherapy, antiretroviral therapy, and wounds and neural diseases.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio's report, Global Erythropoietin Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Amgen
• Hoffmann-LA Roche
• Johnson & Johnson
• Kyowa Hakko Kirin

Other prominent vendors
• Ahua Pharmaceutical
• 3SBio
• BIOSIDUS
• Biocon
• Boehringer Ingelheim
• Chugai Pharmaceutical
• Celltrion
• Intas Pharmaceuticals
• Cipla
• DAICHI SANKYO
• Dr. Reddy's Laboratories
• Teva Pharmaceutical Industries
• Dragon Pharma
• Huaxin High Biotechnology
• JCR Pharmaceuticals
• Shanghai Kehua Bio-Engineering
• LG Life Science
• Novartis
• Pfizer
• Sandoz International
• Shenyang Sunshine Pharmaceutical
• Shenzhen Sai Bao Er Bio-Pharmaceutical
• Sihuan Pharmaceutical
• STADA
• Uni-Bio Science
• Wanbang Biochemical Pharmaceuticals

Market driver
• Increase in chronic kidney disease (CKD) and dialysis patient pool.
• For a full, detailed list, view our report

Market challenge
• Physicians' reluctance to prescribe biosimilars.
• For a full, detailed list, view our report

Market trend
• Advent of biosimilars expected to improve the treatment rates.
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.